Ipilimumab and Pembrolizumab Mixed Response in a 41-Year-Old Patient with SMARCA4-Deficient Thoracic Sarcoma: An Interdisciplinary Case Study

• Published in: Case reports in oncology Vol. 14; no. 2; pp. 706 - 715
• Main Authors: Anžič, Nina, Krasniqi, Fatime, Eberhardt, Anna-Lena, Tzankov, Alexandar, Haslbauer, Jasmin Dionne
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland S. Karger AG 01.05.2021; Karger Publishers
• Subjects: Cancer; Case Report; Case reports; Cell cycle; checkpoint inhibitor; Chemotherapy; Gene expression; Immunotherapy; Interdisciplinary aspects; ipilimumab; Kinases; Lymphatic system; Lymphoma; Medical prognosis; Metastasis; Monoclonal antibodies; Morphology; Mutation; Pain; pembrolizumab; Proteins; Radiation therapy; Sarcoma; smarca4; smarca4-deficient thoracic sarcoma; Targeted cancer therapy; Tumors; Checkpoint inhibitor; Pembrolizumab; Ipilimumab; SMARCA4-deficient thoracic sarcoma; SMARCA4

SMARCA4-deficient thoracic sarcoma is a newly described entity of thoracic sarcomas with a poor prognosis, defined by poorly differentiated epithelioid to rhabdoid histomorphology and SMARCA4 gene inactivation. We present a case of a SMARCA4-deficient thoracic sarcoma in a 41-year-old male with a sm...